Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in egfr addicted cancers

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Zhou, Jian Ping ^a,b   Chen, Xin ^a   Feng, Shan ^a   Luo, Shi Dong ^a   Pan, You Li ^a   Zhong, Lei ^a   Ji, Pan ^a   Wang, Ze Rong ^a   Ma, Shuang ^a   Li, Lin Li ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b PANZHIHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SYNAPTOPHYSIN; ASCORBIC ACID; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; QUINAZOLINE DERIVATIVE;

ALGORITHM; ARTICLE; CANCER CELL DESTRUCTION; CELL ONCOGENE; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE INACTIVATION; HUMAN; HUMAN CELL; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR INTERACTION; PROCESS DEVELOPMENT; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; BIOLOGICAL MODEL; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE SILENCING; GENETICS; METABOLISM; NEOPLASM; ONCOGENE; PATHOLOGY; PHOSPHORYLATION; REPRODUCIBILITY; TUMOR CELL LINE;

ASCORBIC ACID; CELL DEATH; CELL LINE, TUMOR; COMPUTER SIMULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 83355170636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028930     Document Type: Article

References (70)

1. Weinstein IB, (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21: 857-864.
2. Weinstein IB, (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
3. Weinstein IB, Joe AK, (2006) Mechanisms of Disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
4. Huettner CS, Zhang P, Van Etten RA, Tenen DG, (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24: 57-60.
5. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488-501.
6. Hui AB, Or YY, Takano H, Tsang RK, To KF, et al. (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65: 8125-8133.
7. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421.
8. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
10. Hinoda Y, Sasaki S, Ishida T, Imai K, (2004) Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95: 621-625.
11. Mills GB, Lu Y, Kohn EC, (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 98: 10031-10033.
12. Kamb A, (2003) Consequences of nonadaptive alterations in cancer. Mol Biol Cell 14: 2201-2205.
13. Kaelin WG, (2005) The Concept of Synthetic Lethality in the Context of Anticancer Therapy. Nat Rev Cancer 5: 689-698.
14. Felsher DW, (2008) Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 68: 3081-3086.
15. Sharma SV, Fischbach MA, Haber DA, Settleman J, (2006) "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12: 4392s-4395s.
16. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
17. Sawyers C, (2004) Targeted cancer therapy. Nature 432: 294-297.
18. Garber K, (2007) New insights into oncogene addiction found. J Natl Cancer Inst 99: 264-265 269.
19. Faber AC, Wong KK, Engelman JA, (2010) Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 9: 851-852.
20. Kitano H, (2002) Systems Biology: A Brief Overview. Science 295: 1662-1664.
21. Wolkenhauer O, Auffray C, Baltrusch S, Bluthgen N, Byrne H, et al. (2009) Systems Biologists Seek Fuller Integration of Systems Biology Approaches in New Cancer Research Programs. Cancer Res 70: 12-13.
22. Kohl P, Noble D, (2009) Systems biology and the virtual physiological human. Mol Syst Biol 5: 292.
23. Huang S, Ernberg I, Kauffman S, (2009) Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 20: 869-876.
24. Materi W, Wishart DS, (2007) Computational systems biology in drug discovery and development: methods and applications. Drug Discovery Today 12: 295-303.
25. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 304: 1497-1500.
26. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J, (2005) Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124: 71-76.
27. Sasagawa S, Ozaki Y-i, Fujita K, Kuroda S, (2005) Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat Cell Biol 7: 365-373.
28. Borisov N, Aksamitiene E, Kiyatkin A, Legewie S, Berkhout J, et al. (2009) Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst Biol 5: 256.
29. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, et al. (2009) Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis. Sci Signal 2: ra31.
30. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, et al. (2007) Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol 3: 144.
31. Brightman FA, Fell DA, (2000) Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells. FEBS Lett 482: 169-74.
32. Oda K, Matsuoka Y, Funahashi A, Kitano H, (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: E1-E17.
33. Ung CY, Li H, Ma XH, Jia J, Li BW, et al. (2008) Simulation of the regulation of EGFR endocytosis and EGFR-ERK signaling by endophilin-mediated RhoA-EGFR crosstalk. FEBS Lett 582: 2283-2290.
34. Zou J, Luo SD, Wei YQ, Yang SY, (2011) Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry. Mol BioSyst 7: 169-179.
35. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, et al. (2009) Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol 5: 239.
36. Schlessinger J, (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
37. Waterman H, Yarden Y, (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490: 142-152.
38. Voice JK, Klemke RL, Le A, Jackson JH, (1999) Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 274: 17164-17170.
39. Kolch W, (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 Pt 2: 289-305.
40. Meakin SO, MacDonald JI, Gryz EA, Kubu CJ, Verdi JM, (1999) The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation. J Biol Chem 274: 9861-9870.
41. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, et al. (2006) Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem 281: 19925-19938.
42. Rintelen F, Stocker H, Thomas G, Hafen E, (2001) PDK1 regulates growth through Akt and S6K in Drosophila. Proc Natl Acad Sci U S A 98: 15020-15025.
43. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, et al. (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101: 16419-16424.
44. Benhar M, Dalyot I, Engelberg D, Levitzki A, (2001) Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress. Mol Cell Biol 21: 6913-6926.
45. Tikhomirov O, Carpenter G, (2003) Ligand-induced, p38-dependent Apoptosis in Cells Expressing High Levels of Epidermal Growth Factor Receptor and ErbB-2. J Biol Chem 279: 12988-12996.
46. Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, et al. (2003) p38 Mitogen-activated Protein Kinase Sensitizes Cells to Apoptosis Induced by Different Stimuli. Mol Biol Cell 15: 922-933.
47. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, et al. (2007) p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis. Cancer Cell 11: 191-205.
48. Park HS, Lee SH, Park D, Lee JS, Ryu SH, et al. (2004) Sequential Activation of Phosphatidylinositol 3-Kinase, Pix, Rac1, and Nox1 in Growth Factor-Induced Production of H2O2. Mol Cell Biol 24: 4384-4394.
49. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, et al. (1997) Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272: 217-221.
50. Jin H, Heller DA, Kalbacova M, Kim JH, Zhang J, et al. (2010) Detection of single-molecule H2O2 signalling from epidermal growth factor receptor using fluorescent single-walled carbon nanotubes. Nat Nanotechnol 5: 302-309.
51. Hsieh CC, Papaconstantinou J, (2006) Thioredoxin-ASK1 complex levels regulate ROS-mediated p38 pathway activity in livers of aged and long-lived Snell dwarf mice. FASEB J 20: 259-268.
52. Zhang R, Luo D, Miao R, Bai L, Ge Q, et al. (2005) Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24: 3954-3963.
53. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, et al. (2003) AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278: 23432-23440.
54. Wang Z, Yang H, Tachado SD, Capo-Aponte JE, Bildin VN, et al. (2006) Phosphatase-Mediated Crosstalk Control of ERK and p38 Signaling in Corneal Epithelial Cells. Invest Ophthalmol Visual Sci 47: 5267-5275.
55. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, et al. (2007) BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. PLoS Med 4: e315.
56. Lebel CP, Ischiropoulos H, Bondy SC, (1992) Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 5: 227-231.
57. Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, et al. (2000) G alpha(i) and G alpha(o) are target proteins of reactive oxygen species. Nature 408: 492-495.
58. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, et al. (2010) Ros-mediated amplification of akt/mtor signalling pathway leads to myeloproliferative syndrome in foxo3-/- mice. Embo J 29: 4118-4131.
59. Trachootham D, Alexandre J, Huang P, (2009) Targeting cancer cells by ros-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.
60. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10: 241-252.
61. Pelicano H, Carney D, Huang P, (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updates 7: 97-110.
62. Qutub AA, Popel AS, (2008) Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1 Differentially in Cancer and Ischemia. Mol Cell Biol 28: 5106-5119.
63. Raddatz E, Thomas AC, Sarre A, Benathan M, (2011) Differential contribution of mitochondria, NADPH oxidases, and glycolysis to region-specific oxidant stress in the anoxic-reoxygenated embryonic heart. Am J Physiol Heart Circ Physiol 300: H820-835.
64. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, et al. (2005) ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6: 587-592.
65. Liao Y, Hung MC, (2003) Regulation of the Activity of p38 Mitogen-Activated Protein Kinase by Akt in Cancer and Adenoviral Protein E1A-Mediated Sensitization to Apoptosis. Mol Cell Biol 23: 6836-6848.
66. Reinehr R, Schliess F, Haussinger D, (2003) Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation. FASEB J 17: 731-733.
67. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ, (2003) The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 278: 21938-21943.
68. Faber AC, Li D, Song Y, Liang MC, Yeap BY, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106: 19503-19508.
69. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, et al. (2008) Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22: 1191-1199.
70. Trachootham D, Zhang H, Zhang W, Feng L, Du M, et al. (2008) Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112: 1912-1922.